[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperparathyroidism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperparathyroidism":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,50,86,115,155,175,201],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100624883","parathyroidectomy-after-kidney-transplantation-100624883",false,"NCT07415421","Parathyroidectomy After Kidney Transplantation","Subtotal Parathyroidectomy for the Treatment of Persistent Hyperparathyroidism After Kidney Transplantation","Para-KiT","Inclusion criteria\n\n* Age \\> 18 years and legally competent and able to understand spoken and written Danish\n* Kidney transplantation ≥6 months prior (no upper limit of time after transplantation)\n* Stable kidney graft function, defined as estimated GFR ≥ 30 ml\u002Fmin\u002F1.73m3\n* On minimum two separate biochemical measurements:\n\nPTH \\> upper normal limit of assay and\n\n* serum ionized calcium ≥1.33 mmol\u002FL or\n* serum total calcium ≥2.60 mmol\u002FL or\n* serum phosphate ≤0.60 mmol\u002FL despite sufficient dietary intake\n\nwith measurements obtained within\n\n* 3 months in patients 6-12 months post-transplant\n* 6 months in patients \\>12 months post-transplant\n\nand not attributable to calcium supplementation or treatment with thiazide diuretics or lithium.\n\nExclusion criteria\n\n* Inability to provide written, informed consent\n* Current anti-resorptive therapy (bisphosphonate, denosumab)\n* Current bone anabolic therapy (teriparatide, romosozumab)\n* Previous surgical parathyroidectomy\n* Not considered fit for surgery (including pregnancy)\n* Ionized calcium ≥1.50 mmol\u002FL or albumin-corrected calcium ≥3.00 mmol\u002FL despite discontinuation of calcium supplements.","ALL","18 Years",{"count":20,"type":21},85,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to clarify whether surgical treatment of persistent hyperparathyroidism after kidney transplantation offers clinically meaningful benefits compared with a conservative treatment strategy.\n\nKidney transplant recipients (\\>6 mo after transplantation) with persistent hyperparathyroidism (elevated PTH and either hypercalcemia or hypophosphatemia) will be randomized in a 1:1 ratio to either subtotal parathyroidectomy or conservative management according to standard clinical practice. The study is conducted as an open-label, randomized controlled pilot trial with a 12-month follow-up period.\n\nOutcomes include bone density, physical function, quality of life and symptom burden.",[27,28],"Hyperparathyroidism","Kidney Transplantation Recipients",[30,31,32,33,34,35,36],"Persistent hyperparathyroidism","Kidney transplant recipients","Parathyroidectomy","Bone mineral density","Muscle function","Quality of life","Randomized controlled trial","RECRUITING","2026-06-25",{"date":40,"type":41},"2026-06-26","ACTUAL",{"date":43,"type":41},"2026-03-03",{"date":45,"type":21},"2030-12-31",{"name":47,"class":48},"Aarhus University Hospital","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":49},"100599366","routine-validation-and-reproducibility-testing-of-laboratory-assays-and-research-techniques-used-for-endocrine-cardiometabolic-and-musculoskeletal-disorder-research-vald-100599366","NCT07083557","Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)","VALD","Inclusion Criteria:\n\n* ≥18 and ≤100 years of age\n* body mass index ≥16.0 and ≤60 kg\u002Fm2\n\nExclusion Criteria:\n\n* \\\u003C18 and \\>100 years of age\n* body mass index \\\u003C16.0 or \\>60 kg\u002Fm2\n* allergies, intolerances, or dietary restrictions to meal ingredients, vegans or vegetarians\n* use of medications or dietary supplements (e.g., anti-inflammatories, immune modulators, etc) that could interfere with the particular assay\u002Ftechniques being evaluated\n* engaged in regular structured exercise \\>150 min per week unless needed for validation of the assay\u002Ftechnique being evaluated\n* significant organ system dysfunction or diseases, except those that are sought for validation of the assay\u002Ftechnique being evaluated\n* alcohol use disorder as defined by the National Institute of Alcohol Abuse and Alcoholism or use of controlled substances unless alcohol use disorder is required for validation of the assay\u002Ftechnique being evaluated\n* pregnant women, persons who smoke, prisoners, and inability to grant voluntary informed consent.",true,"100 Years",{"count":60,"type":21},100,"OBSERVATIONAL","The purpose of this research study is to validate (check the accuracy of) laboratory assays, intravenous catheter insertion, and equipment or devices and their reproducibility, which is necessary to perform high quality research on chronic diseases, nutrition, and metabolism (the process by which a substance is handled in the body) at the University of Missouri. As technology changes and uses new testing methods, it is necessary to compare results from old tests, equipment and devices and new tests, equipment, or devices and the reproducibility of these measurements to make sure the results are accurate. Reproducibility means performing the same test more than once to see if the same results can be achieved each time. This study will look at the validation and reproducibility of tests and laboratory assays in participants who are healthy or affected by relevant endocrine, cardiometabolic, and musculoskeletal disorders.",[64,65,66,67,68,69,70,27,71,72,73,74,75,76],"Obesity and Obesity-related Medical Conditions","Diabetes","Atherosclerotic Disease","Heart Failure","MASH","Sarcopenia","Osteoporosis","Hypoparathyroidism","Ischemic Heart Disease","Cystic Fibrosis (CF)","Chronic Kidney Disease(CKD)","Osteopenia","Cachexia","2026-05-05",{"date":79,"type":41},"2026-05-07",{"date":81,"type":21},"2027-01-01",{"date":83,"type":21},"2030-07-01",{"name":85,"class":48},"Bettina Mittendorfer",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":93,"maxAge":58,"enrollmentInfo":94,"targetDuration":96,"studyType":61,"phases":4,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":49},"100600929","parathyroidectomy-and-mobility-study-100600929","NCT07103876","Parathyroidectomy and Mobility Study","Rescuing Mobility Function Through Surgical Removal of the Parathyroid Gland","Inclusion:\n\n* Age ≥ 60 years;\n* Biochemical diagnosis of hypercalcemic (corrected serum calcium \\>10.2 mg\u002FdL or ionized serum calcium \\>1.31 mmol\u002FdL or 5.2 mg\u002FdL on at least one serum sample) primary hyperparathyroidism as determined by board-certified endocrinologist or endocrine surgeon;\n* Undergoing parathyroidectomy at UF Health;\n* Willing and able to give informed consent.\n\nExclusion:\n\n* Failure to provide informed consent;\n* Biochemical diagnosis of eucalcemic primary hyperparathyroidism (corrected serum calcium ≤10.2 mg\u002FdL or ionized serum calcium ≤1.31 mmol\u002FdL or 5.2 mg\u002FdL on at least one serum sample);\n* Elected not to undergo parathyroidectomy at UF Health;\n* Major surgery as deemed by principal investigator or hip\u002Fknee replacement in the past 6 months;\n* Fractures to the hands, arms or legs within the last 6 months;\n* Traumatic accident (i.e. motor vehicle collision, fall from elevation, etc.) resulting in orthopedic trauma or requiring prolonged immobilization (\\>2 weeks) within the last 6 months;\n* Blood transfusion within the past 3 months;\n* Self-reported myocardial infarction, cerebrovascular accident, or unstable angina within the past 6 months;\n* NYHA Class 3 or 4 congestive heart failure;\n* Major psychiatric disorder;\n* Cancer requiring treatment in the past 1 year (including metastatic cancer), except for locally treated non-melanoma skin cancers or cancers that have clearly been cured or in the opinion of the investigator carry an excellent prognosis (e.g., Stage 1 cervical cancer);\n* Renal failure requiring hemodialysis or peritoneal dialysis\n* Use of bone-modifying therapies (alendronate \\[Fosamax\\], zoledronic acid \\[Reclast\\], denosumab \\[Prolia or Xgeva\\], or romosozumab \\[Evenity\\]) within 1 month of planned surgery\n* Planning to permanently leave the area within 3 months of parathyroidectomy;\n* Vision or hearing impairment - defined as unable to read or listen\u002Ffollow instructions despite the use of maximal assistive devices (i.e. contact lenses, glasses, hearing aids, etc.)\n* Participating in another clinical trial or has received an investigational product within 30 days prior to screening\u002Fenrollment.","60 Years",{"count":95,"type":21},80,"6 Months","This study evaluates whether surgical removal of the parathyroid gland (parathyroidectomy) improves physical function and mobility in older adults with primary hyperparathyroidism (PHPT). PHPT, a common endocrine disorder in older adults, is associated with reduced muscle strength, mobility, and quality of life. This prospective observational study will enroll up to 80 participants aged 60 and older undergoing parathyroidectomy at UF Health. Participants will complete physical performance tests, wear an Actigraph device to assess physical activity, and provide blood samples for biomarker analysis at pre- and post-operative time points. The goal is to characterize changes in physical function and activity following surgery and to identify biomarkers that may predict mobility improvements. Findings will help inform future larger-scale studies and could expand surgical indications for PHPT in older adults.",[27,99,100],"Parathyroid","Mobility",[102,103,32,104,105],"Physical Function","Inflammatory Biomarkers","Aging","Physical activity","2025-09-23",{"date":108,"type":41},"2025-09-29",{"date":110,"type":41},"2025-08-15",{"date":112,"type":21},"2027-03-31",{"name":114,"class":48},"University of Florida",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":123,"targetDuration":125,"studyType":61,"phases":4,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":49},"100593741","dual-channel-near-infrared-autofluorescence-imaging-and-ai-analysis-to-locate-parathyroid-glands-ptfinder-100593741","NCT07010380","Dual-Channel Near-Infrared Autofluorescence Imaging and AI Analysis to Locate Parathyroid Glands (PTFinder)","A Multicenter Prospective Paired Observational Study Evaluating the Performance of the PTFinder Dual-Channel Near-Infrared and White-Light Imaging System With AI-Assisted Analysis for Rapid Identification of Parathyroid Glands in Surgical Specimens","PTFinder","Inclusion Criteria:\n\n* Age ≥18 years.\n* Scheduled for elective total thyroidectomy, hemithyroidectomy, or parathyroidectomy with removal of thyroid\u002Fparathyroid tissue.\n* Able and willing to provide written informed consent for participation and specimen imaging.\n\nExclusion Criteria:\n\n* History of neck irradiation or prior neck surgery that may distort parathyroid anatomy.\n* Pregnancy or breastfeeding.\n* Confirmed or suspected parathyroid carcinoma, or thyroid carcinoma requiring en-bloc parathyroid resection.\n* Inability to understand the study procedures or to comply with follow-up.",{"count":124,"type":21},180,"7 Days","This study tests PTFinder, a dual-camera system that makes parathyroid glands glow on screen by capturing their natural near-infrared autofluorescence. After a thyroid or parathyroid operation, the removed tissue is scanned with PTFinder and then checked again under normal white light. We will measure how fast (seconds) and how accurately the device finds real glands, confirmed by frozen pathology or a rapid PTH strip. About 180 adult patients at three Chinese hospitals will join. The imaging adds only a few minutes and does not change any part of the surgery. We will also record blood calcium and PTH at 1 h, 24 h, and 7 d after surgery to see whether better gland recovery lowers low-calcium risk.Collected images will also be used to train and test a deep-learning model for fully automated parathyroid recognition; model performance metrics constitute secondary outcomes.",[128,27,129],"Thyroid Neoplasms","Parathyroid Gland",[131,132,133,134,135,136,137,138,139,140,141,142,143,144,145],"Near-Infrared Autofluorescence (NIRAF)","Parathyroid Identification","PTFinder Device","Dual-Channel Imaging","Rapid PTH Test Strip","Thyroidectomy Specimen","Ex-Vivo Fluorescence Camera","Sensitivity and Specificity","Artificial Intelligence","Deep Learning","Computer Vision","NIRAF 3 Dual","PTFinder 3 Dual","PTFinder 3.0 Dual","NIRAF 3.0 Dual","2025-06-14",{"date":148,"type":41},"2025-06-18",{"date":150,"type":41},"2025-06-01",{"date":152,"type":21},"2029-12-31",{"name":154,"class":48},"Bo Wang,MD",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":161,"targetDuration":163,"studyType":61,"phases":4,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":49},"100577410","establishment-of-a-registry-of-patients-with-parathyroid-disease-100577410","NCT06797934","Establishment of a Registry of Patients With Parathyroid Disease","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of hyperparathyroidism or hypoparathyroidism based on biochemical parameters (calcemia, parathormone, phosphormia, creatinine, albumin, vitamin D25OH)\n* Obtaining informed consent\n\nExclusion Criteria:\n\n* none",{"count":162,"type":21},1200,"10 Years","Establishment of a registry with which to census all patients under the care of the O.U. Endocrinology for parathyroid pathology in order to longitudinally evaluate biochemical, clinical, radiological, medico-nuclear and histological data in future studies.",[27,71],"2025-01-22",{"date":168,"type":41},"2025-01-29",{"date":170,"type":41},"2022-01-03",{"date":172,"type":21},"2039-12-31",{"name":174,"class":48},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":184,"conditions":185,"keywords":186,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":49},"100513313","nuclear-medicine-diagnostic-and-artificial-intelligence-100513313","NCT05963841","NUclear MEdicine DIagnostic and Artificial Intelligence","Contribution to Disease Diagnosis and Prognosis Based on the Fusion of Expert Knowledge, Nuclear Medicine Imaging and Artificial Intelligence (AI) Tools","NUMEDIA","Inclusion Criteria:\n\n* Men and women over 18 years of age who underwent dual-isotope parathyroid scintigraphy.\n* No refusal to use data for research purposes\n* Retrospective data (after 13\u002F04\u002F2022: Date of posting of patient information in the department) and prospective data\n\nExclusion Criteria:\n\n* Patient refusal to use data for research purposes\n* Patients who did not benefit from the standard acquisition protocol (123I injection followed by 99mTc 3 hours after LEHR, PINHOLE and SPECT\u002FCT acquisitions)",{"count":49,"type":21},"Artificial intelligence algorithms for parathyroid adenoma detection in parathyroid scans The aim of the study is to develop programs for the automatic subtraction of planar and tomographic parathyroid images and for the localization of parathyroid adenomas using artificial intelligence tools.\n\nInclusion criteria Patients having undergone a double isotope parathyroid diagnostic examination using the standard Besançon University Hospital protocol (double injection of 123I and 99mTc, pinhole image, low energy high resolution (LEHR) and (single-photon emission tomography \u002F Computed tomography) SPECT\u002FCT +\u002F- (positron emission tomography (PET) Choline).\n\nSecondary endpoints Concordance between diagnoses made by nuclear physicians using both methods (current method and new treatment method).",[27],[187,188,189,190,191],"scintigraphy","parathyroid","SPECT\u002FCT","Intelligence artificial","dual isotope","2024-02-06",{"date":194,"type":41},"2024-02-07",{"date":196,"type":41},"2023-08-01",{"date":198,"type":21},"2027-08",{"name":200,"class":48},"Centre Hospitalier Universitaire de Besancon",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":17,"minAge":207,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":210,"briefSummary":211,"conditions":212,"keywords":215,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":49},"100490512","effects-of-multiple-mega-dose-of-vitamin-d3-supplementation-on-ameliorating-moderate-to-severe-chronic-pain-in-hemodialysis-patients-100490512","NCT05667090","Effects of Multiple Mega-dose of Vitamin D3 Supplementation on Ameliorating Moderate to Severe Chronic Pain in Hemodialysis Patients","Inclusion Criteria:\n\n1. Haemodialysis subject ≥ 20 years old\n2. iPTH \\> 250 pg\u002FmL\n3. Chronic pain with visual analogue scale (VAS) score ≥ 4\n4. Voluntary to check serum 25(OH)D levels two times by his\u002Fher own payment during the study\n5. Sign the informed consent\n\nExclusion Criteria:\n\n1. Used to participate in other clinical trials\n2. Chronic liver disease\n3. Sarcoidosis or multiple myeloma","20 Years",{"count":209,"type":21},120,[24],"Pain is a major complaint in hemodialysis (HD) patients. Concentrations of parathyroid hormone (PTH) \\>250 pg\u002Fml are associated with chronic pain. Visual Analogue Scale (VAS) score which is used to assess the pain severity is positively related to PTH levels. This study is aimed to assess the effects of multiple mega dosages vitamin D supplementations in HD patients with chronic pain. It's a single-center, parallel, double-blind randomized control trial that administrations of 576,000 IU once a week of vitamin D3 for 4 weeks or placebo are for 120 eligible subjects. VAS and laboratory tests including serum concentrations of 25(OH)D, calcium, phosphorus, PTH and C-reactive protein will be evaluated.",[213,214,27],"Hemodialysis","Chronic Pain",[216,217,218,219],"Vitamin D supplementation","Mega-dose vitamin D","Cholecalciferol","Chronic pain","2023-03-29",{"date":222,"type":41},"2023-03-30",{"date":224,"type":41},"2023-03-15",{"date":226,"type":21},"2027-12-31",{"name":228,"class":48},"Taipei Medical University Hospital"]